Screen-detected vs clinical breast cancer: the advantage in the relative risk of lymph node metastases decreases with increasing tumour size by Bucchi, L et al.
Screen-detected vs clinical breast cancer: the advantage in the
relative risk of lymph node metastases decreases with increasing
tumour size
L Bucchi*,1, A Barchielli
2, A Ravaioli
1, M Federico
3, V De Lisi
4, S Ferretti
5, E Paci
6, M Vettorazzi
7, S Patriarca
8,
A Frigerio
9, E Buiatti
10 and the SCREENREG Working Group
11
1Romagna Cancer Registry, Luigi Pierantoni Hospital, Forlı`47100, Italy;
2Epidemiology Unit, ASL 10, Firenze, Italy;
3Modena Cancer Registry, Modena,
Italy;
4Parma Cancer Registry, Parma, Italy;
5Ferrara Cancer Registry, Ferrara, Italy;
6Tuscany Cancer Registry/Epidemiology Unit, CSPO, Firenze, Italy;
7Veneto Cancer Registry, Padova, Italy;
8Piedmont Cancer Registry, CPO Piemonte, Torino, Italy;
9First Screening Centre, Torino, Italy;
10Tuscany Regional
Health Agency, Firenze, Italy
Screen-detected (SD) breast cancers are smaller and biologically more indolent than clinically presenting cancers. An often debated
question is: if left undiagnosed during their preclinical phase, would they become more aggressive or would they only increase in size?
This study considered a registry-based series (1988–1999) of 3329 unifocal, pT1a-pT3 breast cancer cases aged 50–70 years, of
which 994 were SD cases and 2335 clinical cases. The rationale was that (1) the average risk of lymph node involvement (Nþ)i s
lower for SD cases, (2) nodal status is the product of biological aggressiveness and chronological age of the disease, (3) for any breast
cancer, tumour size is an indicator of chronological age, and (4) for SD cases, tumour size is specifically an indicator of the duration of
the preclinical phase, that is, an inverse indicator of lead time. The hypothesis was that the relative protection of SD cases from the
risk of Nþ and, thus, their relative biological indolence decrease with increasing tumour size. The odds ratio (OR) estimate of the
risk of Nþ was obtained from a multiple logistic regression model that included terms for detection modality, tumour size category,
patient age, histological type, and number of lymph nodes recovered. A term for the detection modality-by-tumour size category
interaction was entered, and the OR for the main effect of detection by screening vs clinical diagnosis was calculated. This increased
linearly from 0.05 (95% confidence interval: 0.01–0.39) in the 2–7mm size category to 0.95 (0.64–1.40) in the 18–22mm category.
This trend is compatible with the view that biological aggressiveness of breast cancer increases during the preclinical phase.
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The objectives of mammography screening are to detect small
tumours and prevent them from growing to a larger size and
becoming lethal (Tabar et al, 1999). As effectiveness of early
detection in reducing breast cancer mortality has been demon-
strated, there seems to be no doubt that this is the case for a
significant proportion of screen-detected (SD) cases. However, SD
cancers are not only smaller than clinically presenting cancers but
also more indolent biologically as they are lower histological grade,
express p53 and Ki-67 nuclear proteins less frequently, and have
fewer mitotic cells, more moderate/rich oestrogen and progester-
one receptor levels, and lower levels of microvessel density
(Uyterlinde et al, 1991; Hakama et al, 1995; Moezzi et al, 1996;
Tabar et al, 1999; Groenendijk et al, 2000; Ernst et al, 2002). An
often debated question (Thomas, 1995) is: if left undiagnosed
during their preclinical phase, would they become biologically
more aggressive or would they only increase in size?
The only objective method to determine whether biological
behaviour of preclinical breast cancer worsens over time is to
periodically take and analyse cell samples or tissue specimens from
SD lesions surgically untreatable. As no such observations have
ever been reported, current knowledge is based on cross-sectional
comparisons of SD lesions with clinically presenting tumours.
The SCREENREG study was conducted by a group of Italian
cancer registries to evaluate the effect of mammography screening
on the trends in stage-specific incidence of breast cancer. Among
its secondary objectives was to investigate the question of
biological progression of the preclinical disease.
MATERIALS AND METHODS
General methods of the SCREENREG study are reported in detail
elsewhere (Buiatti et al, 2002, 2003). In brief, each participating
registry contributed a consecutive series of breast cancer cases
(International Classification of Diseases for Oncology (ICD-O)
topography code 174) registered before and after implementation
of the local screening programme. Staging and treatment
information was retrospectively retrieved and prospectively
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ycollected by trained personnel with a review of original pathology
and clinical case records. Data were submitted to the coordinating
centre according to a common set of variables. These included the
following: original index number; date of birth; date of registra-
tion; histological type (ICD-O morphology code); simultaneous
bilaterality (yes, no); multifocality (yes, no); surgical treatment
(unknown, unperformed, conservative, radical); tumour size
(invasive component) in mm; pT category according to tumour,
node, metastasis (TNM) classification; number of axillary lymph
nodes recovered; number of positive axillary lymph nodes; pN
category; distant metastases (yes, no/unknown); and detection
modality (SD, death certificate only, clinical diagnosis). Women
with simultaneous bilateral cancers were classified according to the
lesion with the highest pN (or pT in the case of equal pN).
Rationale
Starting from the universal observation that the average risk of
lymph node involvement is lower for SD breast cancer cases
compared with clinically diagnosed cases, the rationale of the
current study was based on the following assumptions: (1) axillary
lymph node status is the product of biological aggressiveness and
chronological age of the disease (Mittra and MacRae, 1991), (2) for
any breast cancer case, tumour size is an indicator of its
chronological age, and (3) for SD cases, tumour size is specifically
an indicator of the duration of the preclinical phase, that is, an
inverse indicator of lead time (Anderson et al, 1991; Norden et al,
1997; Ernst et al, 2002). We evaluated the tumour size-specific risk
of lymph node involvement for SD cases relative to that for clinical
cases. The study hypothesis was that the relative protection of SD
cases from the risk of nodal involvement (and thus, their relative
biological indolence) decreases with increasing tumour size, that
is, with increasing duration of the preclinical phase or decreasing
lead time. If this hypothesis was true, then it would be suggested
that biological characteristics of breast cancer worsen progres-
sively during the preclinical phase.
As reported elsewhere (Buiatti et al, 2003), the SCREENREG
study showed an incidence increase of early-stage breast cancer
following introduction of screening that was only partially
explained by the proportion of SD cases. As this was compatible
with a concomitant diffusion of spontaneous screening outside
organised programmes, the series of breast cancers registered in
the last 5 years prior to screening implementation was considered
a more reliable comparison group.
Case series
The SCREENREG database included 20258 cases. Selection of
eligible cases was based on the following criteria. First, we
excluded all records from three cancer registries supplying only
prescreening cases or cases with unknown tumour size in mm. The
study was restricted to seven provinces situated in northern Italy
(Torino, Parma, Modena, Ferrara, Ravenna, Forlı `-Cesena, and
Rimini). The total female population was about 2300000, that is,
8% of Italian women according to 1991 census. The year of
registration varied between 1988 and 1999. The year of first
implementation of screening for women aged 50–69 years was
1992 for Torino, 1995 for Modena, 1996 for Ravenna and Forlı `-
Cesena, 1997 for Ferrara and Rimini, and 1998 for Parma. The
years of screening covered by the study varied between 1 and 4.
Second, we excluded the clinical cases registered in the years
when each local screening programme was ongoing, the cases
registered 45 years before the implementation of each pro-
gramme, and the cases aged o50 or 470 years (a considerable
proportion of cases detected by mammography at age 69 years
were surgically treated and registered at age 70 years).
Third, we excluded the cases with the following characteristics:
registration with death certificate only; ICD-O morphology code of
sarcoma, lymphoma, and leukaemia; ICD-O behaviour code 2 or
pTis according to TNM classification; tumour size of 1mm or
pT1mic; no evidence of primary tumour or pT0; pT4; presurgical
chemotherapy; surgical treatment unperformed or unknown; and
multifocality.
There remained 4055 potentially eligible cases of invasive,
surgically treated, unifocal, pT1a-pT3 breast carcinoma aged 50–
70 years. These comprised 1111 SD cases and 2944 clinically
presenting cases. The current analysis considered only those cases
undergoing axillary dissection and classified for tumour size in
mm, number of lymph nodes recovered, and pN. These numbered
994 (89%) among SD cases and 2335 (79%) among clinical cases,
for a total of 3329 (82%).
Statistical analysis
General characteristics of SD cases were compared with those of
clinically diagnosed cases using the Kruskal–Wallis test (distribu-
tion by age and number of lymph nodes recovered) and the w
2 test
(distribution by histological type and tumour size). As shown in
Figure 1, the frequency distribution of tumour size was found to be
compatible with a major phenomenon of rounding-up to the
nearest multiple of 5mm. To reduce biases, tumour size was
categorised as 2–7, 8–12, 13–17, 18–22, 23–27, and X28mm.
As a first step in data analysis, the odds ratio (OR) estimate
(with 95% confidence interval (CI)) of the risk of nodal
involvement for SD cases compared with clinical cases was
calculated for each tumour size category. Total OR was adjusted
for tumour size category using the Mantel–Haenszel method. In
both groups of cases, the association of tumour size with nodal
status was evaluated with the w
2 test for trend.
A multiple logistic regression model (model #1) was then built
that included terms for detection modality, tumour size category,
patient age (as a continuous variable), histological type (ductal,
lobular, tubular, other), number of lymph nodes recovered
(continuous), and registry. These were removed from the model
if the likelihood ratio statistic based on the maximum-likelihood
estimates had a probability greater than 0.10.
A term for the detection modality-by-tumour size category
interaction was then entered. The objective of this second (#2)
model was to determine whether the relative risk of lymph node
involvement for SD cases compared with clinically detected cases
varied in relation to tumour size category. The OR associated with
detection modality was calculated as
logitðpðxÞÞ ¼ a þ b1x1 þ b2x2 þ   þb5x5 þ b6x6 þ   þb9x9
þ b10x10 þ   þbpxp
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Figure 1 Frequency distribution of study cases (n¼3329) by detection
modality and tumour size.
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variables for tumour size category, x6, y, x9 are the dummy
variables for the detection modality-by-tumour size interaction,
and x10 to xp are the other covariates. Significance of interaction
was tested with the deviance w
2 test.
Adequacy of model #2 was examined with the goodness-of-fit
test. In addition, points or cases for which the model did not fit
sufficiently were identified with the calculation of the standardised
residuals or outliers, the leverage points, and the delta–beta
points. As original records could not be retrieved and checked for
coding and data-entry errors, all of these were removed (model #3)
and analysis was repeated.
Finally, the OR for the main effect of detection by screening in
model #3 was computed as expðb1Þ for the 2–7mm size category,
and expðb1þbjÞ (where j¼2, y, 5) for the subsequent categories
(Kleinbaum and Klein, 2002).
RESULTS
The median age was 61 years in both groups of cases. SD cancers
had a more favourable distribution by tumour size (P¼0.000),
with 73% cases p17mm vs 48%, a greater median number of
axillary lymph nodes recovered (17 vs 15, P¼0.000), and a
distribution by histological type (ductal, 80%; lobular, 14%;
tubular, 3%; other, 2%) similar to that of clinical cases (ductal,
80%; lobular, 13%; tubular, 2%; other, 4%).
Table 1 shows that the average proportion of SD cases with
positive lymph nodes, 23%, was lower than that of clinically
detected cases, 40%. The crude OR was 0.44. After adjustment for
tumour size category, overall protection from the risk of lymph
node involvement decreased to 0.62 (95% CI: 0.52–0.75). In both
groups, the proportion of node-positive cases was positively
associated with tumour size (P¼0.000). However, it increased
more steeply among SD cases. This led the size-specific OR to
roughly increase until a diameter of 22mm.
Table 2 shows the results of the first two logistic models fitted.
In model #1, after simultaneous adjustment for tumour size,
patient age, number of axillary lymph nodes recovered, and
histological type, SD cases showed a significantly lower risk of
lymph node involvement (OR¼0.59).
Model #2 revealed a significant detection modality-by-tumour
size interaction (deviance w
2¼13.78, df¼5, P¼0.017). Although
irregularly, the risk of lymph node involvement for SD cases
relative to that of clinical cases increased with increasing tumour
size. The OR for the effect of detection by screening was 0.33 when
the tumour size was 2–7mm (reference category). Data in the
table indicate that the OR was 0.33 1.57 (or 0.52) in the 8–12mm
size category, 0.33 1.28 in the 13–17mm size category, and
so on.
In model #2, 49 standardised residuals (four of which were
also delta–beta points) and 35 leverage points (three of which
were also delta–beta points) were identified. After exclusion
of these cases, analysis was repeated (model #3) (Table 3).
The results showed a stronger detection modality-by-tumour size
interaction. With a size of 2–7mm, detection by screening
appeared to be associated with an OR as low as 0.05. The other
ORs in the table must be interpreted like those resulting from
model #2.
Table 4 gives the final outcome of analysis. The OR for the
main effect of detection by screening was computed from the
results of model #3. It appears that, taking the detection modality-
by-tumour size interaction into account after exclusion of
residuals and leverage points, the risk of nodal metastases
increased linearly with increasing tumour size and approached
unity among cases 18–22mm in diameter. Although with border-
line significance, the OR was below unity for the last two size
categories.
DISCUSSION
As expected, the average proportion of patients with lymph node
metastases was lower among SD cases than it was among clinically
presenting cases. Moreover, it was positively associated with
tumour size in both groups. With increasing tumour size, however,
it increased more steeply among SD cases. Accordingly, analysis of
interaction demonstrated that the relative risk of lymph node
involvement for preclinical cancers increased with increasing
tumour size. In other words, their relative advantage was
progressively eroded. If our assumption of tumour size of SD
cases as a proxy inverse indicator of lead time is valid, then our
results are compatible with the interpretation that the biological
aggressiveness of breast cancer increases progressively during the
preclinical phase.
This does not explain why, after progressively approaching
unity, the relative risk of nodal metastases decreased again –
although at a borderline level of significance – for SD cases of
larger size. Owing to the paucity of such cases (Table 1), their
behaviour might be subject to random variation. A similar
observation, however, was also reported from the Edinburgh
Randomised Breast Screening Project (Anderson et al, 1991). The
hypothesis we raise points to the fact that most years of screening
covered by this study were the initial years of each local
programme. As large tumour size suggests short or virtual lead
time, the relative risk of nodal metastases for those cases is likely
due to the presence of poorly aggressive diseases detected at
prevalence screen. If so, a consistent and comprehensive
interpretation of results is that (1) a small subset of SD cancers
with a relatively stable biological indolence actually exist, (2) they
become apparent only among the few large-sized cases detected at
Table 1 Univariate analysis of the risk of axillary lymph node metastases
Lymph node
metastases
Tumour size
and detection
modality
Total no.
of cases No Yes (%)
Crude
OR 95% CI
2–7mm
Clinical 147 126 21 (14.3) 1.00 Referent
SD 177 167 10 (5.6) 0.36 0.16–0.80
8–12mm
Clinical 479 371 108 (22.6) 1.00 Referent
SD 328 283 45 (13.7) 0.55 0.37–0.80
13–17mm
Clinical 492 301 191 (38.8) 1.00 Referent
SD 219 170 49 (22.4) 0.45 0.31–0.66
18–22mm
Clinical 537 312 225 (41.9) 1.00 Referent
SD 142 81 61 (43.0) 1.04 0.72–1.52
23–27mm
Clinical 249 125 124 (49.8) 1.00 Referent
SD 64 38 26 (40.6) 0.69 0.39–1.21
X28mm
Clinical 431 166 265 (61.5) 1.00 Referent
SD 64 30 34 (53.1) 0.71 0.42–1.21
Total
Clinical 2335 1401 934 (40.0) 1.00 Referent
SD 994 769 225 (22.6) 0.44 0.37–0.52
OR¼odds ratio; SD¼screen detected; CI¼confidence interval.
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true preclinical SD lesions, their stable biological behaviour is
overwhelmed by those cases for which the relative risk of nodal
metastases is inversely related to lead time.
Our findings are at variance with some previous studies. In
particular, the common statement (Klemi et al, 1992; Norden et al,
1997; Molino et al, 2000; Heimann et al, 2002) that the risk of nodal
involvement adjusted for tumour size is lower for SD cancers was
demonstrated to be misleading, although formally correct. With a
size-specific pattern of relative risk such as that shown in Table 1,
tumour size qualifies as an interaction factor rather than a
confounder. This is equivalent to saying that adjustment for
tumour size obscures the real effect of this variable on the relative
risk of nodal involvement. Using a study design similar to our own,
Tabar et al (1987) failed to demonstrate a significant detection
modality-by-tumour size interaction. The statistical power of the
study, however, was insufficient for this effect to be formally
evaluated.
The current investigation confirms one observation reported by
Anderson et al (1991). In a case series from the Edinburgh
Randomised Breast Screening Project, SD cancers had a crude
(univariate) advantage in the frequency of positive lymph nodes
that decreased progressively from pT1a to pT1c lesions. Moreover,
our findings are compatible with those by Ernst et al (2002), who
observed univariate differences between some biological charac-
teristics of SD and clinical cases that were restricted to lesions
p20mm in diameter. Assuming that lymph node status for any
given tumour size reflects the biological aggressiveness of the
disease, this study also adds support to the view that malignancy
grade of preclinical breast cancer increases with increasing tumour
size (Duffy et al, 1991; Tabar et al, 1999).
Could there be alternative explanations for our results? In the
first place, we have to consider that the proportion of potentially
eligible cases included into analysis was smaller for clinical cases.
The difference, however, was limited (79 vs 89%). Moreover, there
is no specific reason to believe that the observed trend in the
relative risk of nodal involvement reflected a selection bias, if any.
Another problem is that screening may be responsible for
overdiagnosis of nonaggressive cancers (Holmberg et al, 1992). In
a pooled estimate, these accounted for 10–20% of cases detected in
three screening trials (Wald et al, 1994). In many studies, however,
no evidence for overdiagnosis was obtained (Peeters et al, 1989;
Olsen et al, 2003). Most importantly, no published data support an
inverse association between overdiagnosis and tumour size, that is,
the conditio sine qua non for this phenomenon to be considered a
potential explanation for our results.
Overdiagnosis may also result from histological misinterpreta-
tion of benign lesions as malignant. As small tumours are expected
to be highly differentiated, the risk of this type of overdiagnosis
occurring is inversely related to lesion size and, thus, is greater
among SD cases (Holmberg et al, 1992). It clearly appears,
however, that size stratification of analysis made this potential
problem to have no influence, unless one speculates that
impalpability itself conveys a greater risk of misinterpretation.
Moreover, the hypothesis that lesions detected by mammography
Table 2 Multivariate analysis of the risk of axillary lymph node
metastases
Model Covariates of interest
a P-value
Adjusted
OR
b 95% CI
#1
c Detection modality
Clinical 1.00 Referent
SD 0.000 0.59 0.49–0.71
#2
d Detection modality
2–7mm
Clinical 1.00 Referent
SD 0.006 0.33 0.15–0.73
Detection modality-by-tumour
size interaction 0.018
8–12mm
SD 0.315 1.57 0.65–3.77
13–17mm
SD 0.578 1.28 0.54–3.06
18–22mm
SD 0.013 3.04 1.27–7.29
23–27mm
SD 0.170 1.97 0.75–5.19
X28mm
SD 0.134 2.07 0.80–5.37
SD¼screen detected; CI¼confidence interval.
aBoth models included also terms for
patient age (continuous variable), histological type (ductal, lobular, tubular, other),
number of lymph nodes recovered (continuous), and tumour size. The variable
‘registry’ was removed from model #1 as nonsignificantly contributing to its likelihood
(P¼0.6542).
bOR¼odds ratio; ORs from model #2 are to be interpreted as follows:
when tumour size was 2–7mm (reference category), the relative risk of lymph node
involvement for SD cases was 0.33; when tumour size was 8–12mm, the relative risk
was 0.33 1.57, and so on.
cGoodness-of-fit test: Pearson’s w
2¼2611.20, df¼2631,
P¼0.6043.
dGoodness-of-fit test: Pearson’s w
2¼2615.04, df¼2626, P¼0.5565.
Table 3 Multivariate analysis of the risk of axillary lymph node
metastases after removal of standardised residuals, leverage points, and
delta–beta points from model #2 in Table 2
Model
a Covariates of interest
b P-value
Adjusted
OR
c 95% CI
#3 Detection modality
2–7mm
Clinical 1.00 Referent
SD 0.004 0.05 0.01–0.39
Detection modality-by-tumour
size interaction 0.000
8–12mm
SD 0.068 7.04 0.87–57.1
13–17mm
SD 0.051 7.92 0.99–63.2
18–22mm
SD 0.006 18.70 2.33–149.8
23–27mm
SD 0.024 11.56 1.38–96.58
X28mm
SD 0.022 12.02 1.44–100.2
SD¼screen detected; CI¼confidence interval.
aGoodness-of-fit test: Pearson’s
w
2¼2381.51, df¼2497, P¼0.9506.
bThe model included also terms for patient age
(continuous variable), histological type (ductal, lobular, tubular, other), number of
lymph nodes recovered (continuous), and tumour size.
cOR¼odds ratio; ORs are to
be interpreted as those from model #2 (Table 2).
Table 4 Risk of axillary lymph node metastases for SD cases vs clinical
cases: estimate of the main effect of detection by screening according to
tumour size category as obtained from model #3
Tumour size (mm) Adjusted OR
a 95% CI
2–7 0.05 0.01–0.39
8–12 0.36 0.23–0.56
13–17 0.40 0.28–0.58
18–22 0.95 0.64–1.40
23–27 0.59 0.33–1.04
X28 0.61 0.35–1.07
SD¼screen detected; CI¼confidence interval.
aOR¼odds ratio; based on model
#3, OR was computed as expðb1Þ for the 2–7mm size category, and expðb1þbjÞ
(where j¼2, y, 5) for the subsequent categories.
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evaluation was more accurate in the prescreening years and/or less
accurate in the hospitals involved in screening. In fact, an opposite
time trend and a higher standard of quality in breast surgery
reference hospitals are more conceivable, if any.
One related hypothesis is that study results were biased by
differences in accuracy of histopathological staging. The observed
relative risk of nodal involvement for small tumours detected by
screening might be accounted for by a systematic overestimate of
their diameter and/or an opposite mismeasurement of clinically
diagnosed lesions. Frequency distribution in Figure 1, however,
suggested that major error in tumour size measurement was a
random one. We also considered that the risk of nodal
involvement in the earliest cases could be biased by differences
in detection of microinvasive carcinomas. In fact, we excluded
such lesions from both study groups. As to lymph node status, SD
cases had a slightly greater median number of lymph nodes
recovered (17 vs 15). This variable, however, was entered into the
multivariate models.
Finally, our results raise questions about mammography
sensitivity. It is generally agreed that mammography is more
sensitive for indolent lesions (Thomas, 1995). If one assumes that
biological characteristics of breast cancer are stable, then our
results may be compatible with the explanation that the tendency
for mammography to be more sensitive for indolent lesions is
concentrated among small tumours and decreases with increasing
size. To our knowledge, however, such a hypothesis has never been
raised.
Some methodological limitations in the study design need to be
pointed out. First, the large size of this multicentre study allowed
for a formal analysis of the effect of tumour size on the relative risk
of lymph node involvement. However, the case series was not large
enough to enable the nodal status to be defined as the number of
positive lymph nodes. In particular, the number of SD cases with
X4 positive nodes was negligible. In the reference 2–7mm size
category, there were only two such cases.
Second, a linear increase in the relative risk of nodal metastases
for SD cases – as one would expect from a ‘natural’ phenomenon –
was observed only after removal of residuals, leverage points, and
delta–beta points. Unfortunately, we were unable to check the
original records for coding and data-entry errors, if any. Exclusion
of those cases (model #3) led to an OR as low as 0.05 for the
smallest lesions. Although more reliable for our purposes, this
estimate must be considered with caution.
Third, we could not compare the two study groups of cases for
the biological indicators most commonly used in the literature.
The only item of biological information virtually collected by
Italian cancer registries, that is, tumour grade, was excluded from
the SCREENREG database because of incomplete availability and
poor standardization. However, as pointed out in other studies
similar to our own (Norden et al, 1997; Heimann et al, 2002), nodal
status is the strongest and most objective single indicator of
biological virulence of breast cancer for any given tumour size.
In this study, we attempted to explore one of the most
interesting and uncertain theoretical issues of mammography
screening. We conclude that our results add further support to the
view that biological aggressiveness of breast cancer increases
during the preclinical phase. Our observations suggest that if a
preclinical breast cancer is left undiagnosed, its biological
behaviour worsens before the disease surfaces clinically.
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